Menu

Image of the Day: Glowing Larva

Researchers identified a gene in mosquitoes that moderates their susceptibility to malaria parasite infection. 

Mar 9, 2018
The Scientist Staff, The Scientist Staff

A. gambiae transgenic larva Y. DONG ET AL.Researchers reported yesterday (March 8) in PLOS Pathogens that inactivating the gene FREP1 reduced mosquitoes’ (Anopheles gambiae) susceptibility to Plasmodium, the parasite that causes malaria in humans.

When an A. gambiae mosquito consumes a Plasmodium in a blood meal, the parasite goes through a complex infection cycle as it travels to its host’s salivary gland, from where it infects humans. The Plasmodium’s ability to complete this cycle relies on the activity of several of the mosquito’s proteins. Using CRISPR-Cas9, the team from Johns Hopkins University inactivated the gene encoding fibrinogen-related protein 1 (FREP1), a target they had previously identified as being involved in the infection process. They found that knocking out the gene suppressed Plasmodium infection in mosquitoes. In their paper, the researchers write that the technique is “a potentially powerful approach” to generating infection-resistant mosquitoes.

Y. Dong et al., “CRISPR/Cas9-mediated gene knockout of Anopheles gambiae FREP1 suppresses malaria parasite infection,” PLOS Pathogens, doi:10.1371/journal.ppat.1006898, 2018.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.